Tag Archives: Dengue Fever

The Zika Crisis: Latest Findings | The Forum at HSPH

Marcia Castro
Associate Professor of Demography,
Harvard T.H. Chan School
As of 4th March 2016
– 5900 suspected cases
– 640 confirmed for microcephaly
– Only 80 had zika virus
Note:  Zika (or dengue) found in 80 out of 640 (12.5%) cases of confirmed microcephaly. 87.5% of microcephaly cases tested negative for zika (or dengue) virus. Dengue virus may be creating false positives for zika. Zika and dengue are very similar.

Advertisements

Truth-out: Florida Dengue Fever Outbreak Leads Back to CIA and Army Experiments

http://truth-out.org/archive/component/k2/item/90808:florida-dengue-fever-outbreak-leads-back-to-cia-and-army-experiments
Wednesday, 21 July 2010 12:08
By HP Albarelli Jr and Zoe Martell

Unknown to most Americans is that dengue fever has been the intense focus of US Army and CIA biological warfare researchers for over 50 years. Ed Regis notes in his excellent history of Fort Detrick, “The Biology of Doom,” that as early as 1942 leading biochemists at the installation placed dengue fever on a long list for serious consideration as a possible weapon. In the early 1950s, Fort Detrick, in partnership with the CIA, launched a multi-million dollar research program under which dengue fever and several addition exotic diseases were studied for use in offensive biological warfare attacks. Assumably, because the virus is generally not lethal, program planners viewed it primarily as an incapacitant. Reads one CIA Project Artichoke document: “Not all viruses have to be lethal … the objective includes those that act as short-term and long-term incapacitants.”

Activistpost: Viruses And The GM Insect “Flying Vaccine” Solution

http://www.activistpost.com/2010/12/viruses-and-gm-insect-flying-vaccine.html
DECEMBER 13, 2010
Brandon Turbeville

“…The basic premise behind the flying mosquito vaccines is that an insect will be genetically modified to produce antibodies to a certain disease in their saliva, which is then transmitted to the individual when the mosquito bites them.
There is a host of problems with this method that range from the moral to the scientific. First, the presence of antibodies does not necessarily mean immunity, and the transfer of them does not in any way provide immunization to the subject being injected with them. The science related to antibodies and immunity is still largely unsettled. Vaccines, themselves, are completely ineffective and have never been proven effective by a study that was not connected to a drug company or a pharmaceutical company.[1] They are, essentially, faith-based medicine…”

Full Article: Viruses And The GM Insect “Flying Vaccine” Solution

Intrexon Corporation – Synthetic Biology

http://www.dna.com

“The ability to create and modify ‘organic’ materials on increasingly larger scales has occurred with a number of breakthroughs in genetic engineering including automated DNA sequencing, DNA synthesis, the advent of computational bioinformatics, and the creation of genetically modified organisms. Today, Intrexon’s expertise in designing DNA and constructing complex gene programs utilizing a modular, scalable approach with an embedded capacity to predict the viability of a biological solution, places it at the leading-edge of this growing synthetic biology discipline.”

Aedes aegypti OX513A

http://www.oxitec.com/health/our-products/aedes-agypti-ox513a/
Product profile
OX513A is a bisex RIDL strain. Males are released to mate with wild females. The progeny of such matings die as late larvae or pupae. Continual releases of sufficient numbers of RIDL males will reduce the target population to below the level needed to transmit disease. The late lethality means that RIDL larvae compete with wild-type larvae for resources,adding to the overall effectiveness of control. Before release, male and female pupae are separated mechanically, exploiting the fact that they are naturally significantly different in size. The strain contains the DsRed marker which is clearly visible in larvae, a useful tool for quality control in production and effective monitoring in the field. OX513A is available in Asian and Latin American genetic backgrounds.

Status
OX513A has regulatory approvals for import and contained testing in Brazil, Cayman Islands, France, India, Malaysia, Singapore, Thailand, USA and Vietnam. Open field trials have taken place in both Grand Cayman and Malaysia, and are currently also underway in Brazil.